Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
Authors:
Top Cited Papers
- 1 January 2019
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 75 (1) , 111-128
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomyBMC Cancer, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell CarcinomaClinical Cancer Research, 2011
- The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancerAnnals of Oncology, 2011
- Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomyBJU International, 2010
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206Journal of Clinical Oncology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003